Library

Autor(en) Titel Quelle Links
Cairo MS, Gerrard M, Sposto R, Auperin A, Pinkerton CR, Michon J, Weston C, Perkins SL, Raphael M, McCarthy K, Patte C, FAB LMB96 International Study Committee Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood 2007, 109: 2736    
Cairo MS, Coiffier B, Reiter A, Younes A, TLS Expert Panel Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. British journal of haematology 2010, 149: 578    
Cairo S, Armengol C, Maibach R, Häberle B, Becker K, Carrillo-Reixach J, Guettier C, Vokuhl C, Schmid I, Buendia MA, Branchereau S, von Schweinitz D, Kappler R A combined clinical and biological risk classification improves prediction of outcome in hepatoblastoma patients. European journal of cancer (Oxford, England : 1990) 2020, 141: 30    
Calaminus G, Vesterling-Hörner D, Bokkerink J, Gadner H, Günther G, Haas H, Jürgens H, Teske C, Göbel U The prognostic significance of serum alpha 1-fetoprotein in children and adolescents with malignant extracranial non-testicular germ cell tumors. Klin Pädiatr 1991, 203: 246    
Calaminus G, Teske C, Göbel U Improved prognosis of intracranial germ cell tumors (GCTs), Results of the MAKEI 89 Study. VII European Conference on Clinical Oncology and Cancer Nursing (ECCO). The European Journal of Cancer 1993, 29A    
Calaminus G, Teske C, Göbel U Chemotherapy associated toxicity in patients with malignant nontesticular germ cell tumors (MNGCT). Comparison of MAKEI 83/86 and MAKEI 89. Advances in the Bioscience 1994, 91, 67    
Calaminus G, Andreussi L, Garré ML, Kortmann RD, Schober R, Göbel U Secreting germ cell tumors of the central nervous system (CNS). First results of the cooperative German/Italian pilot study (CNS sGCT). Klinische Padiatrie 1997, 209: 222    
Calaminus G, Wessalowski R, Harms D, Göbel U Juvenile granulosa cell tumors of the ovary in children and adolescents: results from 33 patients registered in a prospective cooperative study. Gynecologic oncology 1997, 65: 447    
Calaminus G, Garre M, Kortmann R, Mann J, Göbel U CNS germ cell tumors in children. Results of the German MAKEI89 protocols and SIOP CNS GCT 93P/96 study. Germ Cell Tumors 1998,IV: 247    
Calaminus G Measuring Quality of Life in Children with Cancer. Med Pediat Oncol 1999, 33    
Calaminus G Health-related quality of life in children with cancer. First results of the PEDQOL Core Questionnaire in German children. Med Pediatr Oncol 1999, 33    
Calaminus G, Haas R, Göbel U Keimzelltumoren. Leitlinien der GPOH, in Reinhardt,D , Creutzig,U , Kiess,W , Luthardt,T , Michalk,D , Schmidt,E , Ulmer,H (eds ) Leitlinien Kinderheilkunde und Jugendmedizin München, Jena: Urban & Fischer 1999    
Calaminus G, Kiebert G Studies on health-related Quality of Life in childhood cancer in the European setting. Int J Cancer 1999, 12: 83    
Calaminus G, Bernbeck B, Weinspach S, Wiener A Spätfolgen bei Kindern und Jugendlichen mit malignen Hirntumoren und ihre Auswirkungen auf die Lebensqualität Monatsschr Kinderheilkunde 2000, 148    
Calaminus G, Langer T, Willich N, Beck J Lebensqualität und Spätfolgen bei Kindern und Jugendlichen mit Krebserkrankungen. Der Onkologe 2000, 6: 868    
Calaminus G, Weinspach S, Janssen G, Wiener A, Göbel U Quality of life (QoL) of survivors of medulloblastoma in childhood and adolescence. Med Pediatr Oncol 2000, 35    
Calaminus G, Weinspach S, Teske C, Göbel U Quality of Life in children and adolescents with cancer. Klin Pädiatrie 2000, 212: 211    
Calaminus G, Weinspach S, Teske C, Göbel U Quality of life in children and adolescents with cancer. First results of an evaluation of 49 patients with the PEDQOL questionnaire. Klinische Padiatrie 2000, 212: 211    
Calaminus G Lebensqualität bei Kindern und Jugendlichen mit Krebserkrankungen. WIR Informationsschrift der Aktion für krebskranke Kinder e.V. (Bonn) 2003, 3    
Calaminus G, Schneider DT, Bökkerink JP, Gadner H, Harms D, Willers R, Göbel U Prognostic value of tumor size, metastases, extension into bone, and increased tumor marker in children with malignant sacrococcygeal germ cell tumors: a prospective evaluation of 71 patients treated in the German cooperative protocols Maligne Keimzelltumoren (MAKEI) 83/86 and MAKEI 89. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003, 21: 781    
Calaminus G Früher erkennen, ob der Krebs zurückkehrt. Newsletter Thema Kinder und Jugendliche Gesundheitsforschung: Forschung für den Menschen Hrsg: Bundesministerium für Bildung und Forschung (BMBF) 2004, 7    
Calaminus G Krebskranke Kinder brauchen mehr als Medikamente. Newsletter Thema Kinder und Jugendliche Gesundheitsforschung: Forschung für den Menschen Hrsg: Bundesministerium für Bildung und Forschung (BMBF) 2004, 7    
Calaminus G Lebensqualität bei Kindern und Jugendlichen mit Hirntumoren. WIR Informationsschrift der Aktion für krebskranke Kinder e.V. (Bonn) 2004, 2: 6    
Calaminus G, Bamberg M, Jürgens H, Kortmann RD, Sörensen N, Wiestler OD, Göbel U Impact of surgery, chemotherapy and irradiation on long term outcome of intracranial malignant non-germinomatous germ cell tumors: results of the German Cooperative Trial MAKEI 89. Klinische Padiatrie 2004, 216: 141    
Calaminus G, Bamberg M, Harms D, Jürgens H, Kortmann RD, Sörensen N, Wiestler OD, Göbel U AFP/beta-HCG secreting CNS germ cell tumors: long-term outcome with respect to initial symptoms and primary tumor resection. Results of the cooperative trial MAKEI 89. Neuropediatrics 2005, 36: 71    
Calaminus G, Weinspach S, Teske C, Göbel U Quality of survival in children and adolescents after treatment for childhood cancer: the influence of reported late effects on health related quality of life. Klinische Padiatrie 2007 May-Jun; 219: 152    
Calaminus G Intrakraniale Keimzelltumoren. Monatsschr Kinderheilkd 2008, 156: 1181–1186    
Calaminus G, Barr R Economic evaluation and health-related quality of life. Pediatric blood & cancer 2008, 50(5 Suppl): 1112    
Calaminus G, Schneider DT, Weissbach L, Schönberger S, Okpanyi V, Leuschner I, Poremba C, Göbel U Survival after an antiangiogenetic therapy and surgery in a wide spread growing teratoma originating from a testicular mixed malignant germ cell tumor. Klinische Padiatrie 2009, 221: 136    
Calaminus G, Göbel U, Schrum J, Wittkugel O, Westphal M, Timmermann B Proton beam therapy for loco-regional control of a recurrent mixed malignant germ cell tumor of the skull in a 22-month-old girl. Klinische Padiatrie 2010, 222: 175    
Calaminus G, Kortmann R, Worch J, Nicholson JC, Alapetite C, Garrè ML, Patte C, Ricardi U, Saran F, Frappaz D SIOP CNS GCT 96: final report of outcome of a prospective, multinational nonrandomized trial for children and adults with intracranial germinoma, comparing craniospinal irradiation alone with chemotherapy followed by focal primary site irradiation for patients with localized disease. Neuro-oncology 2013, 15: 788    
Calaminus G, Birch JR, Hollis R, Pau B, Kruger M The role of SIOP as a platform for communication in the global response to childhood cancer. Pediatric blood & cancer 2013, epub ahead of print    
Calaminus G, Dörffel W, Baust K, Teske C, Riepenhausen M, Brämswig J, Flechtner HH, Singer S, Hinz A, Schellong G Quality of life in long-term survivors following treatment for Hodgkin's disease during childhood and adolescence in the German multicentre studies between 1978 and 2002. Supportive care in cancer 2014, 22: 1519    
Calaminus G, Frappaz D, Kortmann RD, Krefeld B, Saran F, Pietsch T, Vasiljevic A, Garre ML, Ricardi U, Mann JR, Göbel U, Alapetite C, Murray MJ, Nicholson JC Outcome of patients with intracranial non-germinomatous germ cell tumors-lessons from the SIOP-CNS-GCT-96 trial. Neuro-oncology 2017, 19: 1661    
Calaminus G, Jenney M, Hjorth L, Baust K, Bernstein M, Bielack S, Vos P, Hogendoorn PCW, Jovic G, Krailo M, Kreitz K, Marina N, Popoola BO, Sauerland C, Smeland S, Teske C, Schweinitz CV, Whelan J, Wiener A, Sydes MR, Nagarajan R Quality of Life of Patients With Osteosarcoma in the European American Osteosarcoma Study-1 (EURAMOS-1): Development and Implementation of a Questionnaire Substudy. JMIR research protocols 2019, 8:e14406    
Calaminus G, Schneider DT, von Schweinitz D, Jürgens H, Infed N, Schönberger S, Olson TA, Albers P, Vokuhl C, Stein R, Looijenga L, Sehouli J, Metzelder M, Claviez A, Dworzak M, Eggert A, Fröhlich B, Gerber NU, Kratz CP, Faber J, Klingebiel T, Harms D, Göbel U Age-Dependent Presentation and Clinical Course of 1465 Patients Aged 0 to Less than 18 Years with Ovarian or Testicular Germ Cell Tumors; Data of the MAKEI 96 Protocol Revisited in the Light of Prenatal Germ Cell Biology. Cancers 2020, 12    
Calaminus G, Baust K, Berger C, Byrne J, Binder H, Casagranda L, Grabow D, Grootenhuis M, Kaatsch P, Kaiser M, Kepak T, Kepáková K, Kremer LCM, Kruseova J, Luks A, Spix C, van den Berg M, van den Heuvel-Eibrink MMM, van Dulmen-den Broeder E, Kuonen R, Sommer G, Kuehni C Health-Related Quality of Life in European Childhood Cancer Survivors: Protocol for a Study Within PanCareLIFE. JMIR research protocols 2021, 10:e21851    
Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 2011 May 12; 117: 5019    
Campen CJ, Kranick SM, Kasner SE, Kessler SK, Zimmerman RA, Lustig R, Phillips PC, Storm PB, Smith SE, Ichord R, Fisher MJ Cranial irradiation increases risk of stroke in pediatric brain tumor survivors. Stroke; a journal of cerebral circulation 2012, 43: 3035    
Cantu-Rajnoldi A, Biondi A, Jankovic M, Masera G, Rovelli A, Uderzo C, Head D, Raimondi S, Creutzig U, Ritter J Diagnosis and incidence of acute promyelocytic leukemia (FAB M3 and M3 variant) in childhood. Blood 1993, 81: 2209    
Cantu Rajnoldi A, Fenu S, Kerndrup G, van Wering ER, Niemeyer CM, Baumann I, European Working Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS) Evaluation of dysplastic features in myelodysplastic syndromes: experience from the morphology group of the European Working Group of MDS in Childhood (EWOG-MDS). Annals of hematology 2005, 84: 429    
Cappellini MD, Cohen A, Porter J, Taher A, Viprakasit V Guidelines for the Management of Transfusion Dependent Thalassaemia. Thalassemia International Federation 3rd Edition    
Capper D, Jones DTW, Sill M, Hovestadt V, Schrimpf D, Sturm D, Koelsche C, Sahm F, Chavez L, Reuss DE, Kratz A, Wefers AK, Huang K, Pajtler KW, Schweizer L, Stichel D, Olar A, Engel NW, Lindenberg K, Harter PN, Braczynski AK, Plate KH, Dohmen H, Garvalov BK, Coras R, Hölsken A, Hewer E, Bewerunge-Hudler M, Schick M, Fischer R, Beschorner R, Schittenhelm J, Staszewski O, Wani K, Varlet P, Pages M, Temming P, Lohmann D, Selt F, Witt H, Milde T, Witt O, Aronica E, Giangaspero F, Rushing E, Scheurlen W, Geisenberger C, Rodriguez FJ, Becker A, Preusser M, Haberler C, Bjerkvig R, Cryan J, Farrell M, Deckert M, Hench J, Frank S, Serrano J, Kannan K, Tsirigos A, Brück W, Hofer S, Brehmer S, Seiz-Rosenhagen M, Hänggi D, Hans V, Rozsnoki S, Hansford JR, Kohlhof P, Kristensen BW, Lechner M, Lopes B, Mawrin C, Ketter R, Kulozik A, Khatib Z, Heppner F, Koch A, Jouvet A, Keohane C, Mühleisen H, Mueller W, Pohl U, Prinz M, Benner A, Zapatka M, Gottardo NG, Driever PH, Kramm CM, Müller HL, Rutkowski S, von Hoff K, Frühwald MC, Gnekow A, Fleischhack G, Tippelt S, Calaminus G, Monoranu CM, Perry A, Jones C, Jacques TS, Radlwimmer B, Gessi M, Pietsch T, Schramm J, Schackert G, Westphal M, Reifenberger G, Wesseling P, Weller M, Collins VP, Blümcke I, Bendszus M, Debus J, Huang A, Jabado N, Northcott PA, Paulus W, Gajjar A, Robinson GW, Taylor MD, Jaunmuktane Z, Ryzhova M, Platten M, Unterberg A, Wick W, Karajannis MA, Mittelbronn M, Acker T, Hartmann C, Aldape K, Schüller U, Buslei R, Lichter P, Kool M, Herold-Mende C, Ellison DW, Hasselblatt M, Snuderl M, Brandner S, Korshunov A, von Deimling A, Pfister SM DNA methylation-based classification of central nervous system tumours. Nature 2018, 555: 469    
Cappellini MD, Viprakasit V, Taher AT, Georgiev P, Kuo KHM, Coates T, Voskaridou E, Liew HK, Pazgal-Kobrowski I, Forni GL, Perrotta S, Khelif A, Lal A, Kattamis A, Vlachaki E, Origa R, Aydinok Y, Bejaoui M, Ho PJ, Chew LP, Bee PC, Lim SM, Lu MY, Tantiworawit A, Ganeva P, Gercheva L, Shah F, Neufeld EJ, Thompson A, Laadem A, Shetty JK, Zou J, Zhang J, Miteva D, Zinger T, Linde PG, Sherman ML, Hermine O, Porter J, Piga A, BELIEVE Investigators A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia. N Engl journal of Med 2020, 26; 382: 1219    
Carli M, Colombatti R, Oberlin O, Stevens M, Masiero L, Frascella E, Koscielniak E, Treuner J, Pinkerton C High-dose melphalan with autologous stem-cell rescue in metastatic rhabdomyosarcoma. J Clin Oncol 1999, 17: 2796    
Cario G, Stadt U, Reiter A, Welte K, Sykora K Variant translocations in sporadic Burkitt's lymphoma detected in fresh tumour material. Br J Haematol 2000, 110: 537    
Cario H, Stahnke K, Sander S, Kohne E Epidemiological situation and treatment of patients with thalassemia major in Germany: results of the German multicenter beta-thalassemia study. Annals of hematology 2000, 79: 7    
Carlsson G, Fasth A Infantile genetic agranulocytosis, morbus Kostmann: presentation of six cases from the original . Acta paediatrica (Oslo, Norway : 1992) 2001, 90: 757    
Cario G, Stanulla M, Fine B, Teuffel O, Neuhoff V, Schrauder A, Flohr T, Schafer B, Bartram C, Welte K, Schlegelberger B, Schrappe M Distinct gene expression profiles determine molecular treatment response in childhood acute lymphoblastic leukemia. Blood 2005, 105: 821    
Cario G, Izraeli S, Teichert A, Rhein P, Skokowa J, Möricke A, Zimmermann M, Schrauder A, Karawajew L, Ludwig WD, Welte K, Schünemann HJ, Schlegelberger B, Schrappe M, Stanulla M High interleukin-15 expression characterizes childhood acute lymphoblastic leukemia with involvement of the CNS. Journal of clinical oncology 2007, 25: 4813    
Cario G, Fetz A, Bretscher C, Möricke A, Schrauder A, Stanulla M, Schrappe M Initial leukemic gene expression profiles of patients with poor in vivo prednisone response are similar to those of blasts persisting under prednisone treatment in childhood acute lymphoblastic leukemia. Annals of hematology 2008, 87: 709    
Cario G, Zimmermann M, Romey R, Gesk S, Vater I, Harbott J, Schrauder A, Moericke A, Izraeli S, Akasaka T, Dyer MJ, Siebert R, Schrappe M, Stanulla M Presence of the P2RY8-CRLF2 rearrangement is associated with a poor prognosis in non-high-risk precursor B-cell acute lymphoblastic leukemia in children treated according to the ALL-BFM 2000 protocol. Blood 2010,    
Cario H, Grosse R, Janssen G, Jarisch A, Meerpohl J, Strauss G, German hematology societies (GPOH and DGHO) [Guidelines for diagnosis and treatment of secondary iron overload in patients with congenital anemia]. Klinische Padiatrie 2010, 222: 399    
Carlsson G, Winiarski J, Ljungman P, Ringdén O, Mattsson J, Nordenskjöld M, Touw I, Henter JI, Palmblad J, Fadeel B, Hägglund H Hematopoietic stem cell transplantation in severe congenital neutropenia. Pediatric blood & cancer 2011, 56: 444    
Cario H, Kohne, E Thalassämie, Leitlinie der Gesellschäft für Pädiatrische Onkologie und Hämatologie. AWMF online    
Cario H, Grosse R, Janssen G et al. Leitlinie (S2k) zur Diagnostik und Therapie der sekundären Eisenüberladung bei Patienten mit angeborenen Anämien. AWMF online 2015    
Cario G, Rhein P, Mitloehner R, Zimmermann M, Bandapalli OR, Romey R, Moericke A, Ludwig WD, Ratei R, Muckenthaler MU, Kulozik AE, Schrappe M, Stanulla M, Karawajew L High CD45 surface expression determines relapse risk in children with precursor B-cell and T-cell acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol. Haematologica 2013 Aug 2; E-pub ahead of print    
Carroll C, Watson P, Spoudeas HA, Hawkins MM, Walker DA, Clare IC, Holland AJ, Ring HA Prevalence, associations, and predictors of apathy in adult survivors of infantile (<5 years of age) posterior fossa brain tumors. Neuro-oncology 2013, 15: 497    
Cario H, Grosse R, Jarisch A, et al. Leitlinie Sichelzellkrankheit (S2k). AWMF online 2014    
Cario H, Gattermann N Tischatlas Eisenüberladung bei polytransfundierten Patienten. Georg-Thieme-Verlag Stuttgart 2018    
Cario H, Hoferer A, Schmugge M, Sillaber C, Wörmann B Onkopedia Leitline: Beta-Thalassämie. DGHO 2018    
Cario G, Leoni V, Conter V, Attarbaschi A, Zaliova M, Sramkova L, Cazzaniga G, Fazio G, Sutton R, Elitzur S, Izraeli S, Lauten M, Locatelli F, Basso G, Buldini B, Bergmann AK, Lentes J, Steinemann D, Goehring G, Schlegelberger B, Haas OA, Schewe D, Buchmann S, Moericke A, White D, Revesz T, Stanulla M, Mann G, Bodmer N, Arad-Cohen N, Zuna J, Valsecchi MG, Zimmermann M, Schrappe M, Biondi A Relapses and treatment-related events contributed equally to poor prognosis in children with ABL-class fusion positive B-cell acute lymphoblastic leukemia treated according to AIEOP-BFM protocols. Haematologica 2019,    
Cario G, Leoni V, Conter V, Baruchel A, Schrappe M, Biondi A BCR-ABL1-like acute lymphoblastic leukemia in childhood and targeted therapy. Haematologica 2020, Epup ahead of print    
Castleberry R, Pritchard J, Ambros P, Berthold F, Brodeur G, Castel V, Cohn S, De Bernardi B, Dicks-Mireaux C, Frappaz D, Haase G, Haber M, Jones D, Joshi V, Kaneko M, Kemshead J, Kogner P, Lee R, Matthay K, Michon J, Monclair R, Roald B, Seeger R, Shaw P, Shuster J, The International Neuroblastoma Risk Groups (INRG). Eur J Cancer 1997, 33: 2113    
Castiello MC, Scaramuzza S, Pala F, Ferrua F, Uva P, Brigida I, Sereni L, van der Burg M, Ottaviano G, Albert MH, Grazia Roncarolo M, Naldini L, Aiuti A, Villa A, Bosticardo M B-cell reconstitution after lentiviral vector-mediated gene therapy in patients with Wiskott-Aldrich syndrome. The Journal of allergy and clinical immunology 2015, 136: 692-702.e2    
Casali PG, Bielack S, Abecassis N, Aro HT, Bauer S, Biagini R, Bonvalot S, Boukovinas I, Bovee JVMG, Brennan B, Brodowicz T, Broto JM, Brugières L, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dileo P, Dhooge C, Eriksson M, Fagioli F, Fedenko A, Ferraresi V, Ferrari A, Ferrari S, Frezza AM, Gaspar N, Gasperoni S, Gelderblom H, Gil T, Grignani G, Gronchi A, Haas RL, Hassan B, Hecker-Nolting S, Hohenberger P, Issels R, Joensuu H, Jones RL, Judson I, Jutte P, Kaal S, Kager L, Kasper B, Kopeckova K, Krákorová DA, Ladenstein R, Le Cesne A, Lugowska I, Merimsky O, Montemurro M, Morland B, Pantaleo MA, Piana R, Picci P, Piperno-Neumann S, Pousa AL, Reichardt P, Robinson MH, Rutkowski P, Safwat AA, Schöffski P, Sleijfer S, Stacchiotti S, Strauss SJ, Sundby Hall K, Unk M, Van Coevorden F, van der Graaf WTA, Whelan J, Wardelmann E, Zaikova O, Blay JY, ESMO Guidelines Committee, PaedCan and ERN EURACAN Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology : official journal of the European Society for Medical Oncology 2018 Oct 1; 29:iv79-iv95    
Castel D, Philippe C, Kergrohen T, Sill M, Merlevede J, Barret E, Puget S, Sainte-Rose C, Kramm CM, Jones C, Varlet P, Pfister SM, Grill J, Jones DTW, Debily MA Transcriptomic and epigenetic profiling of 'diffuse midline gliomas, H3 K27M-mutant' discriminate two subgroups based on the type of histone H3 mutated and not supratentorial or infratentorial location. Acta neuropathologica communications 2018 Nov 5; 6: 117    
Cattaneo M, Cerletti C, Harrison P, Hayward CP, Kenny D, Nugent D, Nurden P, Rao AK, Schmaier AH, Watson SP, Lussana F, Pugliano MT, Michelson AD Recommendations for the Standardization of Light Transmission Aggregometry: A Consensus of the Working Party from the Platelet Physiology Subcommittee of SSC/ISTH. Journal of thrombosis and haemostasis : JTH 2013, 11: 1183    
Cavazzana A, Schmidt D, Ninfo V, Harms D, Tollot M, Carli M, Treuner J, Betto R, Salviati G Spindle cell rhabdomyosarcoma. A prognostically favorable variant of rhabdomyosarcoma. Am J Surg Pathol 1992, 16: 229    
Cavazzana-Calvo M, Payen E, Negre O, et al. Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia. Nature 2010, 467, 18–322    
Cazzaniga G, De Lorenzo P, Alten J, Röttgers S, Hancock J, Saha V, Castor A, Madsen HO, Gandemer V, Cavé H, Leoni V, Köhler R, Ferrari GM, Bleckmann K, Pieters R, van der Velden V, Stary J, Zuna J, Escherich G, Stadt UZ, Ariò M, Conter V, Schrappe M, Valsecchi MG, Biondi A Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies. Haematologica 2018, 103: 107    
Cecchetto G, Bisogno G, Treuner J, Ferrari A, Mattke A, Casanova M, Dall'Igna P, Zanetti I, Volpato S, Siracusa F, Scarzello G, Boglino C, Carli M Role of surgery for nonmetastatic abdominal rhabdomyosarcomas. Cancer 2003, 97: 1974    
Chang CH, Housepian EM, Herbert C Jr An operative staging system and a megavoltage radiotherapeutic technic for cerebellar medulloblastomas. Radiology 1969, 93: 1351    
del Charco JO, Bolek TW, McCollough WM, Maria BL, Kedar A, Braylan RC, Mickle JP, Buatti JM, Mendenhall NP, Marcus RB Medulloblastoma: time-dose relationship based on a 30-year review. Int J Radiat Oncol Biol Phys 1998, 42: 147    
Cham B, Bonilla MA, Winkelstein J Neutropenia associated with primary immunodeficiency syndromes. Seminars in hematology 2002, 39: 107    
Chantada G, Fandino A, Davila MT, Manzitti J, Raslawski E, Casak S, Schvartzman E Results of a prospective study for the treatment of retinoblastoma. Cancer 2004, 100: 834    
Chang ET, Smedby KE, Hjalgrim H, Porwit-MacDonald A, Roos G, Glimelius B, Adami HO Family history of hematopoietic malignancy and risk of lymphoma. J Natl Cancer Inst 2005, 97: 1466    
Chantada G, Doz F, Antoneli CB, Grundy R, Clare Stannard FF, Dunkel IJ, Grabowski E, Leal-Leal C, Rodríguez-Galindo C, Schvartzman E, Popovic MB, Kremens B, Meadows AT, Zucker JM A proposal for an international retinoblastoma staging system. Pediatric blood & cancer 2006, 47: 801    
Chadi M El Saleeby, MD, Brian E Grottkau, MD, Alison M Friedmann, MD, Sjirk J Westra, MD, and Aliyah R Sohani, MD Case 4-2011 — A 4-Year-Old Boy with Back Pain and Hypercalcemia. N Engl J Med 2011 364: 552    
Chao MM, Kuehl JS, Strauss G, Hanenberg H, Schindler D, Neitzel H, Niemeyer C, Baumann I, von Bernuth H, Rascon J, Nagy M, Zimmermann M, Kratz CP, Ebell W Outcomes of mismatched and unrelated donor hematopoietic stem cell transplantation in Fanconi anemia conditioned with chemotherapy only. Annals of hematology 2015, 94: 1311    
Chagtai T, Zill C, Dainese L, Wegert J, Savola S, Popov S, Mifsud W, Vujanic‡ G, Sebire N, Le Bouc Y, Ambros PF, Kager L, O'Sullivan MJ, Blaise A, Bergeron C, Mengelbier LH, Gisselsson D, Kool M, Tytgat GA, van den Heuvel-Eibrink MM, Graf N, van Tinteren H, Coulomb A, Gessler M, Williams RD, Pritchard-Jones K Gain of 1q As a Prognostic Biomarker in Wilms Tumors (WTs) Treated With Preoperative Chemotherapy in the International Society of Paediatric Oncology (SIOP) WT 2001 Trial: A SIOP Renal Tumours Biology Consortium Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2016 Sep 10; 34: 3195    
Chao MM, Thomay K, Goehring G, Wlodarski M, Pastor V, Schlegelberger B, Schindler D, Kratz CP, Niemeyer C Mutational Spectrum of Fanconi Anemia Associated Myeloid Neoplasms. Klinische Padiatrie 2017, 229: 329    
Cheson BD, Cassileth PA, Head DR, Schiffer CA, Bennett JM, Bloomfield CD, Brunning R, Gale RP, Grever MR, Keating MJ, et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 1990, 8: 813    
Cho YJ, Tsherniak A, Tamayo P, Santagata S, Ligon A, Greulich H, Berhoukim R, Amani V, Goumnerova L, Eberhart CG, Lau CC, Olson JM, Gilbertson RJ, Gajjar A, Delattre O, Kool M, Ligon K, Meyerson M, Mesirov JP, Pomeroy SL Integrative Genomic Analysis of Medulloblastoma Identifies a Molecular Subgroup That Drives Poor Clinical Outcome. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010 Dec 6;    
Christiansen N, Christiansen H, Berthold F, Lampert F Transcriptional activity of N-myc and ngf-r in 50 primary human neuroblastomas as predictor for clinical outcome. Int J Oncol 1993, 3: 853    
Christiansen H, Delattre O, Fuchs S, Theobald M, Christiansen N, Berthold F, Lampert F Loss of the putative tumor suppressor-gene locus 1p36 as investigated by a PCR-assay and N-myc amplification in 48 neuroblastomas. Prog Clin Biol Res 1994, 385: 19    
Christiansen H, Sahin K, Berthold F, Hero B, Terpe H, Lampert F Comparison of DNA aneuploidy, chromosome 1 abnormalities, MYCN amplification and CD44 expression as prognostic factors in neuroblastoma. Eur J Cancer 1995, 31A: 541    
Christiansen H, Terpe H, Gonzales M, Wenderhold S, Berthold F, Lampert F Expression of CD44-standard in 182 primary neuroblastomas. Klin Pädiatr 1995, 207: 219    
Christiansen S, Semik M, Dockhorn-Dworniczak B, Rötker J, Thomas M, Schmidt C, Jürgens H, Winkelmann W, Scheld H Diagnosis, treatment and outcome of patients with Askin-tumors. Thorac Cardiov Surg 2000, 48: 311    
Claviez A, Hero B, Schneppenheim R, Berthold F Hepatopathy in patients with stage 4S neuroblastoma. Klin Pädiatr 1996, 208: 221    
Classen C, Fulda S, Friesen C, Debatin K Decreased sensitivity of drug-resistant cells towards T cell cytotoxicity. Leukemia 1999, 13: 410    
Claviez A, Klingebiel T, Beyer J, Nurnberger W, Ehninger G, Suttorp M, Dreger P, Dörffel W, Schmitz N Allogeneic peripheral blood stem cell transplantation following fludarabine-based conditioning in six children with advanced Hodgkin's disease. Annals Hematology 2004, 83: 237    
Claviez A, Tiemann M, Lüders H, Krams M, Parwaresch R, Schellong G, Dörffel W The impact of latent Epstein-Barr virus infection on outcome in children and adolescents with Hodgkin's lymphoma. haematologica 2004    
Claviez A Morbus Hodgkin. in: Gutjahr P (Hrsg.): Krebs bei Kindern und Jugendlichen Deutscher Ärzte-Verlag Köln, 5. Aufl. 2004, 347    
Claviez A, Lakomek M, Ritter J, Suttorp M, Kremens B, Dickerhoff R, Harms D, Berthold F, Hero B Low occurrence of familial neuroblastomas and ganglioneuromas in five consecutive GPOH neuroblastoma treatment studies. European journal of cancer (Oxford, England : 1990) 2004, 40: 2760    
Claviez A Rhabdomyosarkome. in Gutjahr P (Hrsg.): Krebs bei Kindern und Jugendlichen Deutscher Ärzte-Verlag Köln, 5. Aufl. 2004, 461    
Claviez A, Tiemann M, Lüders H, Krams M, Parwaresch R, Schellong G, Dörffel W Impact of latent Epstein-Barr virus infection on outcome in children and adolescents with Hodgkin's lymphoma. J Clin Oncol 2005, 23: 4048    
Classen CF, Teigler-Schlegel A, Rottgers S, Reinhardt D, Dohner K, Debatin KM AML bearing the translocation t(11;17)(q23;q21): involvement of MLL and a region close to RARA, with no differentiation response to retinoic acid. Annals of hematology 2005, 84: 774    
Claviez A Hodgkin-Lymphom. Interdisziplinäre Leitlinie der Deutschen Krebsgesellschaft und der Deutschen Gesellschaft für Pädiatrische Onkologie und Hämatologie 2007    
Claviez A, Canals C, Dierickx D, Stein J, Badell I, Pession A, Mackinnon S, Slavin S, Dalle JH, Chacón MJ, Sarhan M, Wynn RF, Suttorp M, Dini G, Sureda A, Schmitz N, Lymphoma and Pediatric Diseases Working Parties Allogeneic hematopoietic stem cell transplantation in children and adolescents with recurrent and refractory Hodgkin lymphoma: an analysis of the European Group for Blood and Marrow Transplantation. Blood 2009, 114: 2060    
Claus RA, Bockmeyer CL, Budde U, Kentouche K, Sossdorf M, Hilberg T, Schneppenheim R, Reinhart K, Bauer M, Brunkhorst FM, Lösche W Variations in the ratio between von Willebrand factor and its cleaving protease during systemic inflammation and association with severity and prognosis of organ failure. Thrombosis and haemostasis 2009, 101: 239    
Claviez A Hodgkin-Lymphom. Leitlinie der Gesellschaft für Pädiatrische Onkologie und Hämatologie (GPOH) AWMF 2018    
Claus K Was ist eigentlich CAR-T-Zelltherapie? WIR 2020/01    
Clinton C, Gazda HT: Hrsg: Pagon RA, Adam MP, Bird TD, Dolan CR, Fong CT, Smith RJH, Stephens K Diamond-Blackfan Anemia. GeneRevievs 2014    
Cloos J, Zwaan CM, Corthals SL, Goemans BF, Waisfisz Q, Creutzig U, Reinhardt D, Hählen K, Kaspers GJL FLT3/Internal Tandem Duplication in Paired Presentation and Relapse Pediatric AML Samples. Blood 2004, 104[11], 30a.    
Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S, Ferrara F, Fazi P, Cicconi L, Di Bona E, Specchia G, Sica S, Divona M, Levis A, Fiedler W, Cerqui E, Breccia M, Fioritoni G, Salih HR, Cazzola M, Melillo L, Carella AM, Brandts CH, Morra E, von Lilienfeld-Toal M, Hertenstein B, Wattad M, Lübbert M, Hänel M, Schmitz N, Link H, Kropp MG, Rambaldi A, La Nasa G, Luppi M, Ciceri F, Finizio O, Venditti A, Fabbiano F, Döhner K, Sauer M, Ganser A, Amadori S, Mandelli F, Döhner H, Ehninger G, Schlenk RF, Platzbecker U, Gruppo Italiano Malattie Ematologiche dell'Adulto, German-Austrian Acute Myeloid Leukemia Study Group, Study Alliance Leukemia Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med 2013, 369: 111    
Children's Oncology Group Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers. 2014    
Children´s Oncology Group Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent and Young Adult Cancers. 2018, Version 5.0    
Cohena Y, Nagler A Hematopoietic stem-cell transplantation using umbilical-cord blood. Leukemia & lymphoma 2003, 44: 1287    
Cohen Y, Nagler A Umbilical cord blood transplantation--how, when and for whom? Blood reviews 2004, 18: 167    
Cohn SL, Pearson AD, London WB, Monclair T, Ambros PF, Brodeur GM, Faldum A, Hero B, Iehara T, Machin D, Mosseri V, Simon T, Garaventa A, Castel V, Matthay KK, INRG Task Force The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. Journal of clinical oncology 2009, 27: 289    
Cohen KJ, Pollack IF, Zhou T, Buxton A, Holmes EJ, Burger PC, Brat DJ, Rosenblum MK, Hamilton RL, Lavey RS, Heideman RL Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology Group. Neuro-oncology 2011, 13: 317    
Conter V, Schrappe M, Arico M, Reiter A, Rizzari C, Dordelmann M, Valsecchi M, Zimmermann M, Ludwig W, Basso G, Masera G, Riehm H Role of cranial radiotherapy for childhood T-cell acute lymphoblastic leukemia with high WBC count and good response to prednisone. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Münster groups. J Clin Oncol 1997, 15: 2786    
Conter V, Valsecchi MG, Silvestri D, Campbell M, Dibar E, Magyarosy E, Gadner H, Stary J, Benoit Y, Zimmermann M, Reiter A, Riehm H, Masera G, Schrappe M Pulses of vincristine and dexamethasone in addition to intensive chemotherapy for children with intermediate-risk acute lymphoblastic leukaemia: a multicentre randomised trial. Lancet 2007, 369: 123    
Conklin HM, Li C, Xiong X, Ogg RJ, Merchant TE Predicting change in academic abilities after conformal radiation therapy for localized ependymoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008 Aug 20; 26: 3965    
Conter V, Bartram CR, Valsecchi MG, Schrauder A, Panzer-Grümayer R, Möricke A, Aricò M, Zimmermann M, Mann G, De Rossi G, Stanulla M, Locatelli F, Basso G, Niggli F, Barisone E, Henze G, Ludwig WD, Haas OA, Cazzaniga G, Koehler R, Silvestri D, Bradtke J, Parasole R, Beier R, van Dongen JJ, Biondi A, Schrappe M Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood 2010, 115: 3206    
Conran N High Foetal Haemoglobin in Sickle Cell Disease: Not so Protective? EBioMedicine 2015, 2: 102    
Corbacioglu S, Cesaro S, Faraci M, Valteau-Couanet D, Gruhn B, Rovelli A, Boelens JJ, Hewitt A, Schrum J, Schulz AS, Müller I, Stein J, Wynn R, Greil J, Sykora KW, Matthes-Martin S, Führer M, O'Meara A, Toporski J, Sedlacek P, Schlegel PG, Ehlert K, Fasth A, Winiarski J, Arvidson J, Mauz-Körholz C, Ozsahin H, Schrauder A, Bader P, Massaro J, D'Agostino R, Hoyle M, Iacobelli M, Debatin KM, Peters C, Dini G Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial. Lancet 2012, 379: 1301    
Corbacioglu S Early phase clinical trials in pediatric hematology and oncology. Klinische Padiatrie 2012, 224: 197    
Cotterill S, Ahrens S, Paulussen M, Jürgens H, Voute P, Gadner H, Craft A Prognostic factors in Ewing's tumor of bone. J Clin Oncol 2000, 18: 3108    
Cottle TE, Fier CJ, Donadieu J, Kinsey SE Risk and benefit of treatment of severe chronic neutropenia with granulocyte colony-stimulating factor. Seminars in hematology 2002, 39: 134    
Cotter M, Gulmann C, Jeffers M, Smith OP Increased bone marrow angiogenesis in children with severe chronic neutropenia treated with granulocyte colony-stimulating factor. Journal of pediatric hematology/oncology 2004, 26: 504    
Cox K, Price V, Kahr WH Inherited platelet disorders: a clinical approach to diagnosis and management. Expert review of hematology 2011, 4: 455    
Craig F, Abu-Saad Huijer H, Benini F, Kuttner L, Wood C, Feraris PC, Zernikow B IMPaCCT: standards of paediatric palliative care. Schmerz 2008, 22: 401    
Craig TJ, Levy RJ, Wasserman RL, Bewtra AK, Hurewitz D, Obtułowicz K, Reshef A, Ritchie B, Moldovan D, Shirov T, Grivcheva-Panovska V, Kiessling PC, Keinecke HO, Bernstein JA Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. The Journal of allergy and clinical immunology 2009, 124: 801    
Craig TJ, Bewtra AK, Bahna SL, Hurewitz D, Schneider LC, Levy RJ, Moy JN, Offenberger J, Jacobson KW, Yang WH, Eidelman F, Janss G, Packer FR, Rojavin MA, Machnig T, Keinecke HO, Wasserman RL C1 esterase inhibitor concentrate in 1085 Hereditary Angioedema attacks--final results of the I. M.P. A.C. T.2 study. Allergy 2011, 66: 1604    
Creutzig U, Eschenbach C, Ritter J, Schellong G Akute Leukämie bei einem 13jährigen Jungen mit gleichzeitigem Auftreten von Lymphoblasten und Monoblasten. Klinische Pädiatrie 1981, 193: 162    
Creutzig U, Schellong G Differenzierung der akuten Leukämien. Dtsch Med Wochenschr 1981, 106: 1303    
Creutzig U, Ritter J, Langermann H, Riehm H, Henze G, Niethammer D, Jürgens J, Stollmann B, Lasson U, Kabisch H, Wahlen W, Löffler H, Schellong G Akute myeloische Leukämie bei Kindern. Klinische Pädiatrie 1983, 195: 152    
Creutzig U, Schellong G, Ritter J, Sutor A, Riehm H, Langermann H, Jobke A, Kabisch H Improved results in treatment of acute myelogenous leukemia in children - report of the German cooperative AML study BFM-78. Haematology and Blood Transfusion 1983, 28: 46    
Creutzig U, Schellong G, Ritter J, Sutor A, Riehm H, Langermann H, Niethammer D, Löffler H Ergebnisse und Risikoanalyse bei 130 Patienten der kooperativen Studie BFM-78 zur Behandlung der akuten myeloischen Leukämie im Kindesalter. Verhandlungsband Deutsche Krebsgesellschaft 1983, 4: 207    
Creutzig U, Schaaff A, Ritter J, Jobke A, Kaufmann U, Schellong G Akute myeloische Leukemia bei Kindern unter 2 Jahren. Klinische Pädiatrie 1984, 196: 130    
Creutzig U, Ritter J, Riehm H, Langermann H, Henze G, Kabisch H, Niethammer D, Jürgens J, Stollmann B, Lasson U, Kaufmann U, Löffler H, Schellong G Improved treatment results in childhood acute myelogenous leukemia. Blood 1985, 65: 298    
Creutzig U, Ritter J, Budde M, Riehm H, Henze G, Lampert F, Gerein V, Müller-Weihrich S, Niethammer D, Spaar H, Schellong G Aktuelle Ergebnisse der kooperativen AML-Therapiestudien bei Kindern. Klinische Pädiatrie 1986, 198: 183    
Creutzig U, Ritter J, Riehm H, Schellong G Therapy of acute nonlymphoblastic leukemias. Monogr in Paediat 1986, 18: 136    
Creutzig U, Cantu-Rajnoldi A, Ritter J, Romitti L, Odenwald E, Conter V, Riehm H, Masera G Myelodysplastic syndromes in childhood. American Journal Pediatric Hematology Oncology 1987, 9: 324    
Creutzig U, Hoelzer D Myelodysplastische Syndrome. Klinische Pädiatrie 1987, 199: 169    
Creutzig U, Ritter J, Budde M, Jürgens H, Riehm H, Schellong G Treatment results in childhood AML, with special reference to the German studies BFM-78 and BFM-83. Haematology and Blood Transfusion 1987, 31: 30    
Creutzig U, Ritter J, Budde M, Sutor A, Schellong G Early deaths due to hemorrhage and leukostasis in childhood acute myelogenous leukemia. Cancer 1987, 60: 3071    
Creutzig U, Ritter J, Riehm H, Budde M, Schellong G The childhood AML-studies BFM-78 and -83. Haematology and Blood Transfusion 1987, 30: 71    
Creutzig U, Stahnke K, Pollmann H, Sutor A, Ritter J, Budde M, Schellong G The problem of early death in childhood AML. Haematology and Blood Transfusion 1987, 30: 524    
Creutzig U Therapiestudien bei bösartigen Neubildungen. 1988, 9    
Creutzig U, Hofmann J, Ritter J, Schellong G Therapierealisierung und Komplikationen in der Therapiestudie BFM-83 für die akute myeloische Leukämie. Klinische Pädiatrie 1988, 200: 190    
Creutzig U, Ritter J, Niederbierbaum-Koczy G, Harbott J, Schellong G Prognostische Bedeutung der Eosinophilie bei Kindern mit akuter myeloischer Leukämie in den Studien AML-BFM-78 und -83. Klinische Pädiatrie 1989, 201: 220    
Creutzig U, Niederbiermann G, Ritter J, Harbott J, Löffler H, Schellong G Prognostic significance of eosinophilia in acute myelomonocytic leukemia in relation to induction treatment. Haematology and Blood Transfusion 1990, 33: 226    
Creutzig U, Ritter J, Schellong G Identification of two risk groups in childhood acute myelogenous leukemia after therapy intensification in the study AML-BFM-83 as compared with study AML-BFM-78. Blood 1990, 75: 1932    
Creutzig U, Ritter J, Vormoor J, Eschenbach C, Dickerhoff R, Burdach S, Scheel-Walter H, Kühl J, Schellong G Transiente Myeloproliferation und akute myeloische Leukämie bei Säuglingen mit Morbus Down. Klinische Pädiatrie 1990, 202: 253    
Creutzig U, Ritter J, Vormoor J, Eschenbach C, Dickerhoff R, Burdach S, Scheel-Walter H, Kühl J, Schellong G Transient myeloproliferative disorders and acute leukaemias in infants with Down's syndrome. Contrib Oncol 1990, 41: 75    
Creutzig U, Ritter J, Schellong G Intensification of chemotherapy in children with acute myeloid leukemia. Gematol Transfuziol 1991, 36: 16    
Creutzig U, Bender-Götze C, Klingebiel T, Ebell W, Friedrich W, Stollmann-Gibbels B, Schmid H, Suttorp M, Gratwohl A, Heyen P, Ritter J, Schellong G Vergleich der alleinigen Chemotherapie mit der allogenen Knochenmarktransplantation in erster Vollremission bei Kindern mit akuter myeloischer Leukämie in den Studien AML-BFM-83 und AML- BFM-87 - Matched Pair Analyse. Klinische Pädiatrie 1992, 204: 246    
Creutzig U, Ritter J, Heyen P, Berthold F, Henze G, Kabisch H, Lampert F, Niethammer D, Riehm H, Schellong G Effect of cranial irradiation on rate of recurrence in children with acute myeloid leukemia. Initial results of the AML-BFM-87 study. The AML-BFM Study Group. Klin Pädiatr 1992, 204: 236    
Creutzig U, Ritter J, Schellong G, Group for Involvement of the CNS in childhood AML. Haematology and Blood Transfusion 1992, 34: 491    
Creutzig U, Ritter J, Ludwig W, Harbott J, Löffler H, Schellong G Klassifikation der AML nach morphologischen, immunologischen und zytogenetischen Kriterien - Übersicht unter Berücksichtigung der Subtypen in der Studie AML-BFM-87. Klinische Pädiatrie 1993, 205: 272    
Creutzig U, Ritter J, Schellong G, Group for Cranial irradiation is essential in the treatment of childhood acute myelogenous leukemia. Haematology and Blood Transfusion 1993, 36: 468    
Creutzig U, Ritter J, Zimmermann M, Schellong G Does cranial irradiation reduce the risk for bone marrow relapse in acute myelogenous leukemia? J Clin Oncol 1993, 11: 279    
Creutzig U, Ritter J, Zimmermann M, Schellong G Superior results by cranial irradiation in children with acute myelogenous leukemia. Onkologie 1994, 17: 66    
Creutzig U Therapie von Tumoren und malignen Systemerkrankungen des Kindes, in Zeller WJ, zur Hausen H: Onkologie. Ecomed Verlagsgesellschaft Landsberg 1995    
Creutzig U, Graf N Früherkennung von Neoplasien im Kindesalter. (Sonderheft Früherkennung). Onkologie 1995, 18: 24    
Creutzig U, Ritter J, Ludwig W, Niemeyer C, Reinisch I, Stollmann-Gibbels B, Zimmermann M, Harbott J Acute myeloid leukemia in children with Down syndrome. Klin Pädiatr 1995, 207: 136    
Creutzig U, Ritter J, Zimmermann M, Bender-Götze C, Schellong G Bone-marrow transplantation. Lancet 1995, 346: 60    
Creutzig U, Ritter J, Zimmermann M, Bender-Götze C, Schellong G Seven-year survival exceeding 70% without bone-marrow transplantation in first remission in standard risk children with acute myelogenous leukemia. Blood 1995, 86    
Creutzig U, Sperling Ch, Harbott J, Ritter J, Zimmermann M, Löffler H, Riehm H, Schellong G, Ludwig W Clinical significance of surface antigen expression in children with acute myeloid leukemia. Blood 1995, 86: 3097    
Creutzig U Cancer in the children of survivors of acute leukemia or non- Hodgkin's lymphomas in childhood. Strahlenther Onkol 1996, 172: 690    
Creutzig U Diagnosis and treatment of acute myelogenous leukemia in childhood. Cricial Revue Oncology Hematology 1996, 22: 183    
Creutzig U, Ritter J, Harbott J, Zimmermann M, Löffler H, Schwartz S, Lampert F Biological entities in acute myelogenous leukemia according to morphological, cytogenetic and immunological criteria. Haematol Blood Transfus 1996,V: 524    
Creutzig U, Ritter J, Niemeyer C, Stollmann-Gibbels B, Zimmermann M, Reinisch I, Harbott J Down's syndrome and megakaryoblastic leukemia. Haematology and Blood Transfusion 1996, 38: 754    
Creutzig U, Ritter J, Vormoor J, Ludwig W, Niemeyer C, Reinisch I, Stollmann-Gibbels B, Zimmermann M, Harbott J Myelodysplasia and acute myelogenous leukemia in Down's syndrome. A report of 40 children of the AML-BFM Study Group. Leukemia 1996, 10: 1677    
Creutzig U, Ritter J, Zimmermann M, Klingebiel T Prognose von Kindern mit chronischer myeloischer Leukämie. Klinische Pädiatrie 1996, 208: 236    
Creutzig U, Schrappe M Akute Leukämien im Kindesalter. Internist 1996, 37: 982    
Creutzig U, Schrappe M Acute leukemia in childhood. Classification--diagnosis--therapy--prognosis. Internist (Berl) 1996, 37: 982    
Creutzig U, Hermann J, Gadner H, Zimmermann M, Jürgens H, Ritter J Comparison of equipotential doses of daunorubicin and idarubicin during induction. Blood 1997, 90, suppl. 1    
Creutzig U, Ritter J, Zimmermann M, Boos J, Bender-Götze C, Stahnke K Risk factors for survival in children with refractory AML treated according to AML relapse strategies. Haematology and Blood Transfusion 1997, 39: 810    
Creutzig U, Baumann M Spontaneous remission in neonates with Down's syndrome and acute myelogenous leukemia - transient myeloproliferative disease. Onkologie 1998, 21: 184    
Creutzig U, Bender-Götze C, Ritter J, Zimmermann M, Stollmann-Gibbels B, Körholz D, Niemeyer C The role of intensive AML-specific therapy in treatment of children with RAEB and RAEB-t Leukemia 1998, 12: 652    
Creutzig U, Kallage V, Zimmermann M, Müller J, Beck J, Kohne E, Ritter J, Group for Therapy and outcome in children with AML classified as nonresponders. Blood 1998, 92 suppl :    
Creutzig U, Ritter J, Boos J, Zimmermann M, Bender-Gotze C, Stahnke K Prognosis of children with acute myelocytic leukemia after first relapse. Klin Pädiatr 1998, 210: 207    
Creutzig U, Ritter J, Boos J, Zimmermann M, Bender-Götze C, Stahnke K Prognose von Kindern mit AML nach dem ersten Rezidiv. Klin Pädiatr 1998, 210: 207    
Creutzig U Grundlagenforschung. Monatsschr Kinderheilk 1999, 147    
Creutzig U, Jürgens H, Henze G Kompetenznetzwerk Pädiatrische Onkologie und Hämatologie (Editorial). Klin Pädiatrie 1999, 211: 187    
Creutzig U, Ritter J, Zimmermann M, Hermann J, Bender-Götze C, Berthold F, Henze G, Jürgens H, Kabisch H, Niemeyer C, Reiter A, Feldges A, Gadner H, Group for Improved treatment results after risk-adapted intensification of chemotherapy in children with AML. Blood 1999, 94    
Creutzig U, Zimmermann M, Ritter J, Henze G, Graf N, Löffler H, Schellong G Definition of a standard-risk group in children with AML. Br J Haematol 1999, 104: 630    
Creutzig U, Calaminus G Vertikale Vernetzung in der Pädiatrischen Onkologie. Von der Diagnose bis zur Nachsorge. Onkologe 2000, 6: 814    
Creutzig U, Körholz D, Niemeyer C, Kabisch H, Graf N, Reiter A, Scheel-Walter H, Bender-Gotze C, Behnisch W, Hermann J, Mann G, Ritter J, Zimmermann M Toxicity and effectiveness of high-dose idarubicin during AML induction therapy. Klin Pädiatr 2000, 212: 163    
Creutzig U, Körholz D, Niemeyer C, Kabisch H, Graf N, Reiter A, Scheel-Walter H, Bender-Götze C, Behnisch W, Hermann J, Mann G, Ritter J, Zimmermann M 3 x14 mg idarubicin during induction. Results of a pilot study in children with AML. Leukemia 2000, 14: 340    
Creutzig U, Schwager W, Reinhardt D, Klein G, Harbott J, Zimmermann M, Ritter J Secondary acute myeloid leukemia following primary malignancies in Childhood [Abstract]. Blood 2000, 96: 1365    
Creutzig U, Berthold F, Boos J, Fleischhack G, Gadner H, Gnekow A, Graubner U, Henze G, Hermann J, Imbach P, Jürgens H, Kabisch H, Körholz D, Niemeyer C, Reinhardt D, Reiter A, Ritter J, Spaar H, Zimmermann M Improved treatment results in children with AML. Klin Pädiatr 2001, 213: 175    
Creutzig U, Reinhardt D, Ritter J, Schrappe M, Teigler-Schlegel A, Zimmermann M Extramedullary leukemia predicts unfavorable prognosis in children with AML. Blood (suppl) 2001, 98: 3001    
Creutzig U, Reinhardt D, Zimmermann M, Klingebiel T, Gadner Intensive chemotherapy versus bone marrow transplantation in pediatric acute myeloid leukemia. Blood 2001, 97: 3671    
Creutzig U, Ritter J, Zimmermann M, Hermann J, Gadner H, Group for Risk-Adapted Therapy and Randomization in Children with AML. Haematology and Blood Transfusion 2001, 40: 519    
Creutzig U, Ritter J, Zimmermann M, Hermann J, Gadner H, Sawatzki D, Niemeyer C, Schwabe D, Selle B, Boos J, Kühl J, Feldges A Idarubicin improves blast cell clearance during induction therapy in children with AML. Leukemia 2001, 15: 348    
Creutzig U, Ritter J, Zimmermann M, Reinhardt D, Hermann J, Berthold F, Henze G, Jürgens H, Kabisch H, Havers W, Reiter A, Kluba U, Niggli F, Gadner H Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone. J Clin Oncol 2001, 19: 2705    
Creutzig U, Belohradsky BH Infektionsprophylaxe bei hämatologisch-onkologischen Patienten in der Pädiatrie. Berichte der Qualitätssicherungsgruppe der GPOH in Zusammenarbeit mit der AG „Infektionen bei Neutropenie“ der DGPI. Klin Pädiatr 2001, 213 [S1]:A1-A114    
Creut­zig U, Be­l­ohr­adsky B Infektionsprophylaxe bei hämatologisch-onkologischen Patienten in der Pädiatrie Zusammenfassung aus Sonderband. Klin Pädiatr 2001 213 S1 A1-A114    
Creutzig U, Reinhardt D Current controversies. Br J Haematol 2002, 118: 365    
Creutzig U, Reinhardt D, Lehrnbecher T, Zimmermann M Patterns of Failures Related to Intensive Chemotherapy in Childhood AML. Blood 2002, 100: 258b-258b    
Creutzig U, Bielack S, Henze G, Jürgens H, Herold R, Kaatsch P, Klussmann J, Graf N, Reinhardt D, Schrappe M, Zimmermann M Bedeutung der Therapie-Optimierungs-Studien für die erfolgreiche Behandlung krebskranker Kinder – Ein Rückblick auf 25 Jahre Pädiatrische Onkologie. WIR Informationsschrift der Aktion für krebskranke Kinder e.V. (Bonn) 2002, 3: 7    
Creutzig U Akute myeloische Leukämien (AML) bei Kindern. Erstellt im Rahmen der Tagung 2003 für Leukämie- und Lymphompatienten in Leipzig. WIR 2003    
Creutzig U Treatment of acute myeloid leukemia in children, in Pui CH: Treatment of Acute Leukemias, New Directions for Clinical Research. Totowa, NJ: Humana Press Inc 2003, 237    
Creutzig U, Henze G, Bielack S, Herold R, Kaatsch P, Klusmann J, Graf N, Reinhardt D, Schrappe M, Zimmermann M, Jürgens H Krebserkrankungen bei Kindern. Erfolg durch einheitliche Therapiekonzepte seit 25 Jahren. Deutsches Ärzteblatt 2003, 100:A842    
Creutzig U, Henze G, Jürgens H APO (Arbeitsgemeinschaft Pädiatrische Onkologie). Fortschritt durch Zusammenarbeit innerhalb von Studien. Forum DKG 2003, 38    
Creutzig U, Reinhardt D, Zimmermann M, Dworzak M, Stary J Excellent Results In Patients With Downs Syndrome by Standard AML-BFM Therapy with Reduced Drug Intensity. Blood 2003, 102    
Creutzig U, Zimmermann M, Hannemann J, Krämer I, Herold R, Henze G Qualitätssicherung im Kompetenznetz Pädiatrische Onkologie und Hämatologie. Klin Pädiatr 2003, 215: 338    
Creutzig U, Zimmermann M, Reinhardt D, Lehrnbecher T Analysis of Causes of Death During Intensive Chemotherapy According to Treatment Protocol AML-BFM 93. Klin Pädiatr 2003, 215: 151    
Creutzig U Bessere Chancen auf Heilung - Erfolge in der Behandlung von Kindern mit Krebs. Heilberufe 2004, 38    
Creutzig U, Jürgens H, Herold R, Göbel U, Henze G Konzepte der GPOH und des Kompetenznetzes zur Weiterentwicklung und Qualitätssicherung in der Pädiatrischen Onkologie. Klin Pädiatr 2004, 216: 379    
Creutzig U, Reinhardt D, Zimmermann M: AML-BFM Study Group Prognostic Relevance of Risk Groups in the Pediatric AML-BFM Trials 93 and 98. Annals Hematology 2004, 83:S112-S116    
Creutzig U, Zimmermann M, Reinhardt D, Dworzak M, Stary J, Lehrnbecher T Early Deaths and Treatment-Related Mortality in Children Undergoing Therapy for Acute Myeloid Leukemia. J Clin Oncol 2004, 22: 4384    
Creutzig U Studienprotokoll der Therapieoptimierungsstudie AML-BFM 2004. 2004    
Creutzig U und Klusmann JH Chronik der Gesellschaft für Pädiatrische Onkologie und Hämatologie. Eigenpublikation GPOH und KPOH 2004    
Creutzig U, Reinhardt D, Diekamp S, Dworzak M, Stary J, Zimmermann M AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity. Leukemia 2005, 19: 1355    
Creutzig U, Zimmermann M, Ritter J, Reinhardt D, Hermann J, Henze G, Jürgens H, Kabisch H, Reiter A, Riehm H, Gadner H, Schellong G Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials. Leukemia 2005, 19: 2030    
Creutzig U, Reinhardt D Akute myeloische Leukämien. In: Gadner H, Gaedicke G, Niemeyer C, Ritter J, editors. Pädiatrische Hämatologie und Onkologie Berlin, Heidelberg, New York: Springer Verlag, 2006, 690-714.    
Creutzig U Relapsed acute myeloid leukemia, in Pui CH: Childhood Leukemias. Cambridge University Press 2006, 2. Aufl.    
Creutzig U, Zimmermann M, Lehrnbecher T, Graf N, Hermann J, Niemeyer CM, Reiter A, Ritter J, Dworzak M, Stary J, Reinhardt D Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98. Journal of clinical oncology 2006, 24: 4499    
Creutzig U, Zimmermann M Klinische Studien: Planung, Durchführung und Interpretation. In: Gadner H, Gaedicke G, Niemeyer C, Ritter J, editors. Pädiatrische Hämatologie und Onkologie Berlin, Heidelberg, New York: Springer Verlag, 2006, 634    
Creutzig U, Diekamp S, Zimmermann M, Reinhardt D Longitudinal evaluation of early and late anthracycline cardiotoxicity in children with AML. Pediatric blood & cancer 2007, 48: 651    
Creutzig U, Büchner T, Sauerland MC, Zimmermann M, Reinhardt D, Döhner H, Schlenk RF Significance of age in acute myeloid leukemia patients younger than 30 years: a common analysis of the pediatric trials AML-BFM 93/98 and the adult trials AMLCG 92/99 and AMLSG HD93/98A. Cancer 2008, 112: 562    
Creutzig U, Henze G Abschlusssymposium des Kompetenznetzes Pädiatrische Onkologie und Hämatologie. Onkologie 2008, 14: 951    
Cremer, H Hämangiome – Klassifizierung und Therapie-Empfehlungen. pädiatrie hautnah 2009, 2: 133    
Creutzig U, Zimmermann M, Dworzak M, Urban C, Henze G, Kremens B, Lakomek M, Bourquin JP, Stary J, Reinhardt D Favourable outcome of patients with childhood acute promyelocytic leukaemia after treatment with reduced cumulative anthracycline doses. British journal of haematology 2010, 149: 399    
Creutzig U, Herold R, Henze G Results of the Competence Net Pediatric Oncology and Haematology - a View Back. Klinische Padiatrie 2010, 222: 333    
Creutzig U, Tallen G, Bode A, Reinken K, Yiallouros M, Herold R, Henze G Das Informationsportal www. kinderkrebsinfo. de. FORUM 2010 25: 49    
Creutzig U, Tallen G Dobke J, Grüneberg I, Reinken K, Yiallouros M, Henze G Das Informationsportal www. kinderkrebsinfo. de - Internet als Ratgeber über Krebs bei Kindern und Jugendlichen. Onkologische Pharmazie 2010 3: 45    
Creutzig U, Zimmermann M, Bourquin JP, Dworzak MN, Fleischhack G, von Neuhoff C, Sander A, Schrauder A, von Stackelberg A, Ritter J, Starý J, Reinhardt D CNS irradiation in pediatric acute myeloid leukemia: Equal results by 12 or 18 Gy in studies AML-BFM98 and 2004. Pediatr Blood Cancer 2011, [Epub ahead of print]    
Creutzig U, Zimmermann M, Bourquin JP, Dworzak MN, von Neuhoff C, Sander A, Schrauder A, Teigler-Schlegel A, Stary J, Corbacioglu S, Reinhardt D Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16). Blood 2011, 118: 5409    
Creutzig U, Zimmermann M, Bourquin JP, Dworzak MN, Kremens B, Lehrnbecher T, von Neuhoff C, Sander A, von Stackelberg A, Schmid I, Starý J, Steinbach D, Vormoor J, Reinhardt D Favorable outcome in infants with AML after intensive first- and second-line treatment: an AML-BFM study group report. Leukemia 2012, 26: 654    
Creutzig U, Zimmermann M, Bourquin JP, Dworzak MN, von Neuhoff C, Sander A, Schrauder A, Teigler-Schlegel A, Stary J, Corbacioglu S, Reinhardt D Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16). Blood 2011, 118: 5409    
Creutzig U Kommentar: Krebs bei Kindern und Jugendlichen - Versorgung in Zentren. Dtsch Arztebl 2012; 109(1-2): A-18 / B-15 / C-15    
Creutzig U, van den Heuvel-Eibrink MM, Gibson B, Dworzak MN, Adachi S, de Bont E, Harbott J, Hasle H, Johnston D, Kinoshita A, Lehrnbecher T, Leverger G, Mejstrikova E, Meshinchi S, Pession A, Raimondi SC, Sung L, Stary J, Zwaan CM, Kaspers GJ, Reinhardt D, AML Committee of the International BFM Study Group Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. Blood 2012, 120: 3187    
Creutzig U Relapsed acute myeloid leukemia. In: Pui C-H, ed. Childhood Leukemias. Cambridge:. Cambridge University Press; 2012, 421-428.    
Creutzig U, Tallen G Treatment results for children and adolescents with acute myeloid leukemia in Middle and Eastern European countries. memo 2013 6: 5    
Creutzig U ,Zimmermann M, Dworzak MN, Ritter J, Schellong G, Reinhardt D Development of a curative treatment within the AML-BFM studies. Klinische Padiatrie 2013, 225 Suppl 1:S79    
Creutzig U, Zimmermann M, Bourquin JP, Dworzak MN, Fleischhack G, Graf N, Klingebiel T, Kremens B, Lehrnbecher T, von Neuhoff C, Ritter J, Sander A, Schrauder A, von Stackelberg A, Stary J, Reinhardt D Randomized trial comparing liposomal daunorubicin with idarubicin in induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004. Blood 2013, 122: 37    
Creutzig U, Dworzak M, Reinhardt D Akute myeloische Leukämie im Kindesalter - Leitlinie der Gesellschaft für Pädiatrische Onkologie und Hämatologie - AWMF online 02/2013    
Creutzig U, Semmler J, Kaspers GL, Reinhardt D, Zimmermann M Re-induction with L-DNR/FLAG improves response after AML relapse, but not long-term survival. Klinische Padiatrie 2014, 226(6-7): 323    
Creutzig U, Rössig C, Dworzak M, Stary J, von Stackelberg A, Wössmann W, Zimmermann M, Reinhardt D Exchange Transfusion and Leukapheresis in Pediatric Patients with AML With High Risk of Early Death by Bleeding and Leukostasis. Pediatr Blood Cancer 2015 [Epub ahead of print]    
Creutzig U, Dworzak M, Zimmermann M, Bourquin JP, Gruhn B, Fleischhack G, Graf N, Klingebiel T, Kremens B, Lehrnbecher T, von Neuhoff C, von Stackelberg A, Stray J, Reinhardt D Randomised Introduction of 2-CDA as Intensification during Consolidation for Children with High-risk AML--results from Study AML-BFM 2004. Klin Pädiatr 2015, 227: 116    
Creutzig U, Dworzak MN, Zimmermann M, Bourquin JP, Gruhn B, Fleischhack G, Graf N, Klingebiel T, Kremens B, Lehrnbecher T, von Neuhoff C, Stackelberg AV, Starý J, Reinhardt D Additional treatment with 2-Chloro-2-Deoxyadenosine during consolidation in children with high-risk acute myeloid leukemia does not improve survival. Leukemia 2015, 29: 2260    
Creutzig U, Zimmermann M, Reinhardt D, Rasche M, von Neuhoff C, Alpermann T, Dworzak M, Perglerová K, Zemanova Z, Tchinda J, Bradtke J, Thiede C, Haferlach C Changes in cytogenetics and molecular genetics in acute myeloid leukemia from childhood to adult age groups. Cancer 2016, 122: 3821    
Creutzig U, Dworzak MN, Bochennek K, Faber J, Flotho C, Graf N, Kontny U, Rossig C, Schmid I, von Stackelberg A, Mueller JE, von Neuhoff C, Reinhardt D, von Neuhoff N First experience of the AML-Berlin-Frankfurt-Münster group in pediatric patients with standard-risk acute promyelocytic leukemia treated with arsenic trioxide and all-trans retinoid acid. Pediatric blood & cancer 2017, Epub ahead of print    
Creutzig U, Reinhardt D Akute myeloische Leukämien. in Niemeyer CH, Eggert A (Hrsg.): Pädiatrische Hämatologie und Onkologie 2018    
Creutzig U, Dworzak M, von Neuhoff N, Rasche M, Reinhardt D [Acute Promyelocytic Leukemia: New treatment strategies with ATRA and ATO - AML-BFM-Recommendations]. Klinische Padiatrie 2018, 230: 299    
Creutzig U, Dworzak M, Reinhardt D Akute myeloische Leukämie (AML) im Kindes- und Jugendalter. Leitlinie der Gesellschaft für Pädiatrische Onkologie und Hämatologie AWMF    
Niktoreh N, Lerius B, Zimmermann M, Gruhn B, Escherich G, Bourquin JP, Dworzak M, Sramkova L, Rossig C, Creutzig U, Reinhardt D, Rasche M Gemtuzumab ozogamicin in children with relapsed or refractory acute myeloid leukemia: a report by Berlin-Frankfurt-Münster study group. Haematologica 2019, 104: 120    
Creutzig U, Hiddemann W Late Effects after Treatment of Acute Myeloid Leukemia in Childhood and Adolescence. in Beck JD et al. (Hrsg.): Late Treatment Effects and Cancer Survivor Care in the Young, pp 183-188 Springer Nature Switzerland AG 22021    
Crosby LE, Shook LM, Ware RE, Brinkman WB Shared decision making for hydroxyurea treatment initiation in children with sickle cell anemia. Pediatric blood & cancer 2014, Epub ahead of print    
Cuker A, Neunert CE How I treat refractory immune thrombocytopenia. Blood 2016, 128: 1547    
cw Nachsorge ist für alle ein Thema. Pädiatrische Nachrichten 1999, 4    
Czauderna P, Haeberle B, Hiyama E, Rangaswami A, Krailo M, Maibach R, Rinaldi E, Feng Y, Aronson D, Malogolowkin M, Yoshimura K, Leuschner I, Lopez-Terrada D, Hishiki T, Perilongo G, von Schweinitz D, Schmid I, Watanabe K, Derosa M, Meyers R The Children's Hepatic tumors International Collaboration (CHIC): Novel global rare tumor database yields new prognostic factors in hepatoblastoma and becomes a research model. European journal of cancer 2016, 52: 92    
249 items found

The literature database is sorted by the first author's last name - please choose from the alphabet. It comprises the references that were reported by the trial co-ordinating centres and those which are referenced in this information service, for example by the patient information texts.